Research dossier
Clinical research on NAC
8 trials reviewed across 3 indications.
Strongest evidence
COPD and chronic bronchitis (mucolytic)
Mechanism
NAC's free thiol group cleaves disulfide bonds in mucus glycoproteins, reducing viscosity and aiding airway clearance. Separately, NAC restores intracellular glutathione in lung tissue, dampening oxidative stress that drives chronic-bronchitis pathology.
BRONCUS (n=523, 3 years) was negative at 600 mg/day for FEV1 decline and exacerbations. Later trials and the Cazzola 2015 meta-analysis show that 1,200 mg/day reduces exacerbation rates in chronic bronchitis. Mucus-clearance and symptom benefits are real; disease-modification claims are not.
Effect strongest in patients with chronic bronchitis phenotype and mucus hypersecretion. Most retail NAC supplements are 600 mg — half the dose used in the positive exacerbation trials.
Trials cited
BRONCUS — NAC for COPD progression
negative · RCT
Decramer et al., 2005, Lancetn=523Large, long, well-designed RCT in 523 COPD patients. Three years of 600 mg/day NAC did not slow lung-function decline (FEV1) or reduce exacerbations versus placebo at the primary endpoints. The mucolytic story did not translate to disease modification at this dose.
The 600 mg/day dose was later argued to be too low. Subsequent trials (Zheng et al. 2014 PANTHEON; Tse et al. 2013) using 1,200 mg/day showed exacerbation reductions, which feeds into the Cazzola 2015 meta-analysis below.
NAC for chronic bronchitis and COPD exacerbations — meta-analysis
positive · Meta-analysis
Cazzola et al., 2015, European Respiratory ReviewPooled meta-analysis of NAC for chronic bronchitis and COPD exacerbations. Higher-dose trials (1,200 mg/day) consistently reduced exacerbation rates; the 600 mg/day BRONCUS finding looked like an under-dosed outlier in context. Symptom and mucus-clearance benefits were the dominant signal.
Heterogeneity in dose, severity, and follow-up. The exacerbation-reduction effect is modest and best-supported at the 1,200 mg/day dose, not the typical 600 mg supplement-bottle dose.
Psychiatric adjunct (bipolar depression, schizophrenia, trichotillomania)
Mechanism
NAC modulates the cysteine-glutamate antiporter in the prefrontal cortex, normalizing extracellular glutamate. It also restores intracellular glutathione, lowering oxidative stress implicated in mood and psychotic disorders. Mechanistically reasonable; clinically, the effect is modest and inconsistent.
Berk's two 2008 RCTs (n=75 bipolar, n=140 schizophrenia) showed adjunctive NAC reducing depressive and negative symptoms over 24 weeks at 2 g/day. Grant 2009 showed NAC reducing hair-pulling in adult trichotillomania. Costa 2017 was negative for OCD augmentation. The honest read: real signal as adjunct in some conditions, not robust enough to be standalone therapy in any.
Always adjunctive — never replace existing psychiatric treatment with NAC. Effect typically takes 8–12+ weeks to emerge.
NAC adjunct for depressive symptoms in bipolar disorder
positive · RCT
Berk et al., 2008, Biological Psychiatryn=75Double-blind, placebo-controlled RCT. NAC added to standard mood stabilizers reduced depressive symptoms versus placebo at 24 weeks (large effect size on MADRS). Effect emerged late and washed out after discontinuation — consistent with active suppression rather than disease modification.
Small sample for a psychiatric trial. NAC was adjunctive — patients stayed on their existing mood stabilizers. Not evidence that NAC alone treats bipolar depression.
NAC adjunct for negative symptoms in chronic schizophrenia
positive · RCT
Berk et al., 2008, Biological Psychiatryn=140Double-blind, placebo-controlled RCT in 140 patients (84 completers). Adjunctive NAC produced modest improvements in PANSS total and negative-symptom subscales versus placebo. The effect emerged over months and reversed after discontinuation. Authors framed NAC as 'safe and moderately effective' adjunct, not standalone therapy.
Modest effect size and high dropout. The negative-symptom signal is the most clinically interesting because antipsychotics treat negative symptoms poorly — but this is one trial, not a class-changing result.
NAC for trichotillomania (compulsive hair-pulling)
positive · RCT
Grant, Odlaug & Kim, 2009, Archives of General Psychiatryn=50Double-blind, placebo-controlled RCT. Hair-pulling symptoms dropped significantly more on NAC than placebo (p<0.001). 56% of NAC patients were 'much or very much improved' versus 16% on placebo (p=0.003). Effect emerged around week 9. Well tolerated.
Small sample (n=50). A subsequent pediatric replication (Bloch 2013) was negative — the trichotillomania effect may be adult-specific or trial-specific.
NAC augmentation in treatment-resistant OCD
mixed · RCT
Costa et al., 2017, Journal of Clinical Psychiatryn=40Double-blind, placebo-controlled augmentation trial in SRI-resistant OCD. NAC did not separate from placebo on the primary Y-BOCS reduction at 16 weeks. Anxiety subscale improved on NAC. The takeaway: NAC is not a reliable OCD augmentation strategy in SRI-resistant cases at this dose, despite the mechanistic case for glutamate modulation.
Small (n=40). Earlier open-label and small RCT data had been more favorable; this better-designed trial dampened the OCD signal. Highlights why mechanistic plausibility is not the same as replicated clinical effect.
Insulin sensitivity in PCOS
Mechanism
Oxidative stress and impaired glutathione status are documented in PCOS. Restoring glutathione may improve insulin signaling at the receptor level, with downstream reductions in androgen production.
Small open-label trials (Fulghesu 2002, Oner 2011) show NAC improving insulin sensitivity, reducing free androgens, and modestly improving menstrual regularity in PCOS — comparable to metformin in head-to-head data. Useful pilot signal, not a replacement for first-line PCOS metabolic therapy.
Strongest signal in hyperinsulinemic PCOS phenotypes. Modest effect; small short trials.
NAC for insulin sensitivity in PCOS
positive · RCT
Fulghesu et al., 2002, Fertility and Sterilityn=37Insulin AUC after oral glucose tolerance test dropped on NAC and peripheral insulin sensitivity rose. Free testosterone and free androgen index also fell. Effect was strongest in hyperinsulinemic subjects; women with normal insulin responses did not benefit.
Short (5–6 weeks), small (n=37), open-label. Useful as a mechanism-confirming pilot, not a definitive PCOS treatment trial.
4 forms of NAC compared
Standard N-acetylcysteine (capsule)
Oral bioavailability ~6–10% as parent compound; absorbed cysteine fraction is much higher and is the functionally active species
Best forMucolytic, psychiatric adjunct, glutathione precursorThe form used in nearly every clinical trial. Sulfur smell on burping is the most common complaint. Capsules at 600 mg are standard; the COPD exacerbation trials used 1,200 mg/day.
Effervescent NAC (sachet)
Comparable to standard capsules; effervescent format is largely a delivery preference
Best forMucolytic and respiratory use — common in European pharmacy formats (e.g., ACC Long, Fluimucil)European prescription/OTC formats. Same active dose, easier on the stomach for some users.
Liposomal N-acetylcysteine
Manufacturer-claimed enhanced absorption; rigorous human pharmacokinetic comparisons remain limited
Best forMarketed for general antioxidant and immune supportThe clinical-endpoint trials all use standard NAC, not liposomal. Treat the bioavailability premium as plausible but not validated by head-to-head efficacy data.
N-acetylcysteine amide (NACA)
More lipophilic than NAC — higher cell-membrane and BBB penetration in preclinical models
Best forInvestigational; not a standard retail supplement formExperimental form with active research interest. Not yet supported by clinical-endpoint RCTs in humans.
Side effects and drug interactions
Side effects
GI upset and sulfur-burp odor
Common · More common above 1,200 mg/day
The most common complaint at clinical doses. NAC's sulfur group produces a noticeable odor in eructation and breath. Nausea and loose stools are common at 1,200+ mg/day.
Bronchospasm and asthma exacerbation
Uncommon
Inhaled NAC has triggered bronchospasm in case reports; oral NAC has been associated with asthma symptom worsening in a small subset of users. Less common than with the inhaled form.
Worse with:Inhaled NAC, High-dose oral NAC
Histamine release / pseudoallergic reactions
Rare
Anaphylactoid (non-IgE histamine) reactions reported with intravenous NAC for acetaminophen overdose; rare with oral supplementation. Symptoms include flushing, urticaria, rarely angioedema.
Worse with:IV NAC
Headache and fatigue
Uncommon
Reported in a minority of psychiatric-trial participants. Usually transient.
Hypotension (with nitroglycerin)
Severe
NAC potentiates the vasodilatory effect of organic nitrates. Severe hypotension and headache have been reported when NAC is combined with nitroglycerin.
Worse with:All forms
Drug interactions
Additive effect
nitroglycerinisosorbide mononitrateisosorbide dinitrateNAC enhances nitrate-induced vasodilation, dropping blood pressure further than nitrate alone.
Do not combine NAC with organic nitrates without a prescriber's involvement. Severe hypotension is a documented risk.
Combined-effect risk
activated charcoalActivated charcoal binds NAC in the gut, reducing absorption — relevant only in the acute-overdose setting where both are used.
Hospital protocol — separate dosing if both are used; oral NAC is typically the alternative when charcoal cannot be cleared.
Other
carbamazepinevalproateother anticonvulsantsLimited evidence of altered anticonvulsant levels with high-dose NAC; mechanism not fully characterized.
If you take anticonvulsants and want to add NAC, monitor seizure control and discuss with the prescriber.
Combined-effect risk
ACE inhibitorsARBsother antihypertensivesModest additive blood-pressure-lowering reported in some studies.
Generally well tolerated; watch for symptomatic hypotension if multiple agents are combined.
Reduces nutrient status
chemotherapy agents (case-by-case)NAC's antioxidant activity could theoretically blunt oxidative-stress-mediated tumor kill from some chemotherapies. Evidence is mixed and mostly preclinical.
If you are on active cancer treatment, do not start or continue NAC without your oncologist's approval.
Other critical caveats
- Do not combine NAC with nitroglycerin or other organic nitrates without medical supervision — severe hypotension has been reported.
- NAC supplementation is NOT the same as the hospital acetaminophen-overdose protocol. Daily oral capsules do not replicate the IV/oral antidote dosing or its endpoints. The 'liver protection' marketing leans on a borrowed mechanism, not supplement-trial evidence.
- Most psychiatric NAC trials are small, adjunctive, and 24+ weeks long. NAC is not a depression cure, an OCD cure, or a schizophrenia treatment — it is at best an adjunct alongside standard psychiatric care.
- The 'glutathione booster' framing is mechanistic. Oral NAC raises intracellular cysteine availability, which supports glutathione synthesis — but plasma and tissue glutathione increases in healthy people are modest in the studies that have measured them.
- Most retail NAC products are 600 mg/day — the BRONCUS dose that failed for COPD progression. The COPD exacerbation reductions in the meta-analysis come mostly from 1,200 mg/day trials.
- FDA briefly issued warning letters in 2020–2021 arguing NAC was not a lawful dietary supplement (drug-first under DSHEA); the agency has since exercised enforcement discretion and NAC is widely sold, but the legal posture is unusual for a popular supplement.
Frequently asked
Will NAC boost my glutathione?
Mechanistically, yes — oral NAC supplies cysteine, the rate-limiting amino acid for glutathione synthesis. Clinically, the glutathione increase in healthy people is modest in the studies that have measured it. NAC does demonstrably restore depleted glutathione in pathological states (acetaminophen overdose, chronic disease, oxidative stress conditions). The 'detox your liver' marketing oversells what daily supplementation does in healthy adults.How much NAC for COPD or chronic bronchitis?
1,200 mg/day is the dose that consistently reduces exacerbations in the meta-analyses. The classic 600 mg/day dose used in BRONCUS failed at the primary endpoints. If COPD or chronic-bronchitis exacerbation reduction is the goal, the half-dose retail bottle is not where the trial signal lives.Can NAC replace my antidepressant or antipsychotic?
No. The Berk 2008 bipolar and schizophrenia trials, the Grant 2009 trichotillomania trial, and the Costa 2017 OCD trial were all augmentation trials — patients stayed on standard medication and added NAC. Effects emerge over months and disappear after stopping NAC. Treat NAC as a possible adjunct under psychiatric care, not a replacement.Is NAC safe with my heart medication?
One specific contraindication: nitroglycerin and other organic nitrates. NAC potentiates the vasodilation, which can drop blood pressure severely. With ACE inhibitors, ARBs, and other antihypertensives the additive effect is mild and usually well tolerated. With heart failure or coronary disease medication broadly, discuss with the prescriber before starting.Why do my burps smell like sulfur after NAC?
NAC's free thiol group breaks down to release small amounts of hydrogen sulfide and other sulfur compounds. The smell is harmless. Splitting the dose, taking with food, or switching to an effervescent format reduces (but does not eliminate) it. If the smell is intolerable, this is just how NAC behaves.Why was NAC almost banned by the FDA?
In 2020 the FDA issued warning letters arguing that NAC, having been approved as a drug (acetylcysteine) before being marketed as a supplement, did not qualify as a lawful dietary supplement under DSHEA. After industry pushback the FDA announced enforcement discretion, and NAC remains widely sold. The legal status is unusual — a 'sold but not formally vindicated as a supplement' posture — but the safety profile is not the issue; the issue is regulatory definitions.
References
- 01Examine.com — N-acetylcysteine
- 02NIH StatPearls — Acetylcysteine (NCBI Bookshelf)
- 03Cazzola et al., 2015 — NAC for chronic bronchitis or COPD exacerbations meta-analysis
Last reviewed2026-05-07